rais po consum genom
hard quantifi genom market expand
follow recent healthcar confer featur consum genom panel
firesid chat cfo ad link revisit
model acknowledg difficult quantifi total address market
opportun howev mani barrier market growth fade cost
fallen user better manag store data person medicin
tangibl regulatori reimburs landscap still complic move
forward rise consum genom engag gener public moreov
larg scale genom longer concentr hand us/eu academ genom
center dna sequenc becom democrat global still see
market risk concern data privaci complex data analysi variabl
govern fund regulatory/pay uncertainti believ long
runway growth given posit lead genom tool provid
reiter buy rate updat estim rais po
consum genom sourc potenti upsid
long intrigu opportun direct consum dtc consum
genom cg sinc first compani emerg howev market
plagu regulatori headwind lack killer app lower test cost
emerg genet ancestri test well regulatori win caus rapid
acceler cg space past month inde discuss cg
panel test conduct sinc done alon panel
discuss launch helix cg convers well ilmn
result lead us increas microarray array sequenc servic revenu
rais estim chiefli cg see top-lin compound-annual-growth-rate
expect sale yoy
ep also rais
year estim forecast revenu compound-annual-growth-rate higher
revenu ep cash flow estim rais po po
base dcf analysi assum wacc termin growth rate
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
headquart san diego california
consum servic genet analysi
compani proprietari product servic
use research broad spectrum
scientif activ gain greater understand
genet variat biolog function
tool play import role
develop creation molecular test
posit prospect due wide
adopt compani innov genet
analysi tool strong competit posit
impress forward-look product market
strategi although macro competit risk
remain believ compani recent
launch near-term pipelin help
remain forefront
price object base dcf analysi assum wacc
approxim termin growth rate po approxim
revenu estim roughli ep estim consid
justifi given attract long-term outlook genom market compani
technolog leadership new product cycl increas penetr fast-
grow clinic appli market
downsid risk po weaker-than-expect academ fund lower
consum pull-through competit within genet analysi market regulatori
reimburs uncertainti clinic sequenc market acquisit integr
issu grow concern data privaci slower-than-expect uptak new
derik de bruin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
